IGF-1 Interpretation by Decade of Life

What IGF-1 Actually Measures

IGF-1 is a 70-amino-acid peptide produced mainly in the liver in response to pulsatile growth hormone (GH) secretion. Because GH itself is secreted in bursts and has a half-life of roughly 20 minutes, a single GH draw is nearly useless for clinical decisions. IGF-1 has a half-life of 12-15 hours and reflects integrated GH secretion over the prior 24 hours, making it the standard surrogate marker for GH axis activity in clinical practice. [1]

Why Decades Matter More Than a Single Normal Range

Most commercial lab reports print a reference range that spans age 18 to 70 or older as one wide band. That single band obscures the fact that a 35-year-old with an IGF-1 of 110 ng/mL is likely GH deficient, while the same value is unremarkable at 68. The Endocrine Society's 2019 clinical practice guideline on adult GH deficiency (AGHD) explicitly states that "the diagnosis of GHD in adults should be made using stimulation tests in most patients, with IGF-1 serving as a screening tool interpreted against age- and sex-adjusted normative data." [2]

Assay and Sex Considerations

Results vary by platform. The Immulite 2000, Liaison, and iSYS assays each produce systematically different absolute values for the same serum sample, with inter-assay differences reported up to 30%. [3] Women average IGF-1 values roughly 10-15% below men at the same chronological age. Women taking oral estrogen (but not transdermal estrogen) suppress hepatic IGF-1 production by 20-30%; this must be documented before interpretation. [4]

IGF-1 by Decade: Reference Ranges and Clinical Meaning

Age-specific reference data below are drawn primarily from the normative database published by Bidlingmaier et al. (2014) in the Journal of Clinical Endocrinology and Metabolism (N = 15,220 healthy subjects, iSYS platform) and supplemented by the Endocrine Society normative tables. [5] Values are approximate midpoint ranges; the 2.5th-to-97.5th percentile spread is wider and platform-dependent.

Ages 10-19 (Puberty to Late Adolescence)

IGF-1 peaks during mid-puberty, typically between Tanner stages 3 and 5. Values of 200-600 ng/mL (iSYS) are common, with peak concentrations in girls occurring one to two years earlier than in boys owing to earlier pubertal onset. An IGF-1 below 100 ng/mL in a 15-year-old with delayed growth should prompt GH stimulation testing. Pituitary MRI is indicated when stimulation testing confirms deficiency, as craniopharyngioma and other structural lesions must be excluded. [2]

Ages 20-29

GH secretion and IGF-1 begin their gradual decline from the post-pubertal peak. Expected IGF-1 for a healthy 25-year-old ranges from approximately 150-380 ng/mL on the iSYS assay. A result below 120 ng/mL in this decade warrants at least a repeat fasting morning draw to exclude confounders such as malnutrition, poorly controlled type 1 diabetes, or hypothyroidism before pursuing stimulation testing. [1]

This decade is also relevant for athletes and body-composition-focused patients who may be using GH secretagogues such as sermorelin or CJC-1295/ipamorelin. A pre-treatment baseline IGF-1 is essential; values already near the 75th percentile should not be raised further through exogenous therapy. [6]

Ages 30-39

The slope of IGF-1 decline steepens modestly in the 30s. Median values shift to roughly 115-280 ng/mL. This is the decade in which adult-onset GH deficiency most commonly presents symptomatically, often with increased visceral adiposity, reduced lean mass, impaired exercise capacity, and lower quality-of-life scores. [7]

The AGHD consensus workshop published in JCEM in 2021 noted that an IGF-1 below the age-sex-specific 2.5th percentile has specificity exceeding 95% for GH deficiency in patients with a strong clinical pretest probability. [7] In someone aged 35 with known hypothalamic-pituitary disease, an IGF-1 at the 5th percentile is clinically significant even if it falls within the lab's printed reference range.

Ages 40-49

Midlife is when the gap between "normal" and "optimal" becomes most discussed in longevity medicine. Median IGF-1 for a 45-year-old sits near 100-230 ng/mL. The Rancho Bernardo cohort study (N = 883 men and women followed over 20 years) found that men in the lowest IGF-1 quartile had significantly higher all-cause mortality risk compared with the middle two quartiles. [8]

Longevity clinicians often target the upper third of the age-specific reference range as a functional goal during GH peptide therapy, though this target is opinion-based rather than supported by randomized outcome data. A cautious, evidence-anchored approach is to keep IGF-1 within the age-sex normal range and avoid supra-physiologic values. [6]

Ages 50-59

Mean IGF-1 in the 50s falls to roughly 80-200 ng/mL. GH pulse amplitude declines substantially; the pituitary remains responsive but receives less GHRH stimulation from the hypothalamus. This is the decade in which many patients present to hormone-optimization clinics with symptoms that overlap GH deficiency, menopause (women), and testosterone deficiency (men). Parsing the contribution of each axis requires measuring IGF-1, LH, FSH, total and free testosterone, and thyroid panel simultaneously. Treating one axis in isolation without the full picture risks misattributing symptoms. [2]

Oral contraceptive and systemic HRT use remains common in this decade. Any patient on oral estrogen will show a suppressed IGF-1 that does not reflect true GH axis status. Switching to transdermal delivery for four to eight weeks before retesting is the standard clinical workaround when GH deficiency is suspected. [4]

Ages 60-69

By the early 60s, median IGF-1 is approximately 70-170 ng/mL. The physiologic somatopause means most older adults cluster in the lower half of younger adult ranges, and lab printouts frequently flag these results as normal even when clinical GH deficiency is present. The Endocrine Society guideline states clearly that a diagnosis of AGHD requires biochemical confirmation by stimulation testing and should not be made on IGF-1 alone in older adults. [2]

The other concern in this decade is neoplasm surveillance. Because IGF-1 has mitogenic properties, sustained values above the 97.5th percentile should prompt evaluation for acromegaly (pituitary MRI, oral glucose tolerance test with GH suppression) or exogenous GH misuse. A 2022 meta-analysis in The Lancet Diabetes and Endocrinology found that acromegaly is diagnosed on average 7-12 years after onset, with IGF-1 elevation present in virtually all confirmed cases. [9]

Ages 70 and Beyond

IGF-1 below 70-130 ng/mL is typical in healthy septuagenarians and octogenarians. The clinical significance of low IGF-1 in this group is contested. Observational data show a J-shaped mortality curve: both very low and modestly elevated IGF-1 associate with higher mortality risk. The EPIC-Norfolk cohort (N = 4,493, mean follow-up 10 years) showed that IGF-1 in the lowest quartile (below approximately 100 ng/mL) was associated with increased cardiovascular mortality in men aged 45-79, while the highest quartile showed increased cancer risk. [10]

Routine GH therapy is not FDA-approved for age-related somatopause without documented AGHD confirmed by stimulation testing. Prescribing GH to healthy older adults without confirmed deficiency remains off-label and is not supported by current guidelines. [2]

The GH Stimulation Test: When IGF-1 Alone Is Insufficient

IGF-1 as a single value has a reported sensitivity of roughly 50-70% for diagnosing AGHD, depending on the pre-test probability of the population tested. [7] A normal IGF-1 does not rule out GH deficiency, particularly in patients with hypothalamic-pituitary disease, radiation exposure, or traumatic brain injury.

Standard Stimulation Protocols

The glucagon stimulation test (GST) and the insulin tolerance test (ITT) remain the reference standards in the United States. The ITT requires supervised hypoglycemia (glucose below 40 mg/dL) and is contraindicated in patients with seizure disorders or coronary artery disease. The GST (1 mg glucagon IM, GH sampled at 90 and 120 minutes) is now the preferred alternative at most US centers because of its broader safety profile. A peak GH below 3 ng/mL on GST confirms GH deficiency by current Endocrine Society criteria. [2]

Macimorelin (Macrilen), an oral GH secretagogue approved by the FDA in 2017 specifically for AGHD diagnosis, offers a simpler office-based alternative. In the key trial (N = 153), macimorelin at 0.5 mg/kg showed concordance with ITT results in 87% of cases. [11]

When IGF-1 Alone Is Sufficient for Diagnosis

The Endocrine Society 2019 guideline permits diagnosis without stimulation testing in one specific scenario: a patient with three or more confirmed pituitary hormone deficiencies and an IGF-1 below the lower limit of the age-sex reference range. In that context, the positive predictive value exceeds 95%, and stimulation testing can be waived. [2]

Optimal IGF-1 for GH Peptide Therapy Monitoring

Patients prescribed GH secretagogue peptides (sermorelin, CJC-1295, ipamorelin, tesamorelin, or MK-677) need IGF-1 monitored at baseline, at 8-12 weeks after dose titration, and every 6 months during maintenance. The following framework is used by the HealthRX medical team:

Before starting: Obtain fasting AM IGF-1 on the same assay platform that will be used for follow-up. Document oral estrogen use, hypothyroidism status, and recent caloric restriction (each can suppress IGF-1 by 20-40%). [4]

Target range during therapy: Keep IGF-1 within the age-sex-specific reference range for the patient's chronological age. Targeting the 50th-75th percentile for age is a reasonable functional goal. Avoid values exceeding the 97.5th percentile. No randomized trial has demonstrated clinical benefit from supra-normal IGF-1 in adults without confirmed GH deficiency.

Dose adjustment trigger: An IGF-1 below the 25th percentile for age despite adequate peptide dosing suggests poor secretagogue response, non-compliance, concomitant somatostatin excess, or pituitary insufficiency. Stimulation testing may be warranted before escalating dose further. [7]

Safety ceiling: An IGF-1 above the 97.5th percentile on two consecutive draws 4 weeks apart requires dose reduction or treatment pause. Persistently elevated values need pituitary MRI and an oral glucose tolerance test to exclude acromegaly. [9]

Factors That Confound IGF-1 Results

Accurate interpretation requires accounting for several common variables that shift IGF-1 independent of GH axis function.

Factors That Lower IGF-1

Caloric restriction and protein undernutrition can suppress IGF-1 by 40-50% within two weeks. A study in healthy volunteers undergoing a five-day fast showed median IGF-1 fell from 178 ng/mL to 96 ng/mL. [12] Poorly controlled type 1 diabetes, hepatic cirrhosis, hypothyroidism, and oral estrogen therapy each suppress hepatic IGF-1 production by distinct mechanisms. [4]

Factors That Raise IGF-1

Puberty, pregnancy (second and third trimesters), acromegaly, and exogenous GH or GH secretagogue use all raise IGF-1. Resistance exercise raises IGF-1 modestly (5-15%) in most studies, though the effect size is smaller than commonly believed. [13]

Assay Platform and Sample Handling

Hemolysis artificially lowers IGF-1 on some platforms. Samples should be spun and separated within two hours. If a result is clinically discordant, repeat on the same platform with a freshly drawn, non-hemolyzed sample before making treatment decisions.

IGF-1 in the Context of TRT and HRT

Testosterone raises IGF-1 modestly in hypogonadal men (increases of 10-20% are typical with full testosterone replacement), partly through direct hepatic stimulation and partly through increased lean mass driving GH pulsatility. [14] This means a man with low-normal IGF-1 who starts TRT may see a small upward IGF-1 shift without any change in GH axis function. Clinicians should not use this shift to justify withholding GH evaluation if GH deficiency symptoms persist.

In women, progesterone and transdermal estradiol do not substantially alter IGF-1. Oral ethinyl estradiol and oral conjugated equine estrogens suppress hepatic IGF-1 production significantly, as noted above. The Endocrine Society recommends documenting the route of estrogen delivery on every IGF-1 requisition form. [2]

Summary Reference Table: Approximate IGF-1 Median Values by Decade (iSYS Platform)

| Age Range | Men (ng/mL, approx. Median) | Women (ng/mL, approx. Median) | Clinical Note | |-----------|----------------------------|-------------------------------|---------------| | 15-19 | 300-500 | 250-480 | Pubertal peak; wide range normal | | 20-29 | 180-320 | 150-280 | Declining from peak | | 30-39 | 130-250 | 110-220 | Symptomatic AGHD most common onset | | 40-49 | 100-210 | 85-185 | Longevity-medicine monitoring decade | | 50-59 | 80-180 | 70-160 | Confounders (oral HRT) most prevalent | | 60-69 | 70-155 | 60-140 | Stimulation test often needed for Dx | | 70+ | 55-130 | 50-115 | J-curve mortality; GH-Rx not indicated without confirmed AGHD |

Values are approximate medians for reference; use your laboratory's age-sex-specific 2.5th-97.5th percentile intervals for clinical decisions. [5]